Section Arrow
AKRO.NASDAQ
- Akero Therapeutics
Quotes are at least 15-min delayed:2025/08/26 17:43 EDT
After Hours
Last
 48.12
0 (0.00%)
Bid
48.05
Ask
48.1
High 48.12 
Low 47.19 
Volume 29919 
Regular Hours
Last
 48.12
+1.09 (+2.32%)
Day High 
48.14 
Prev. Close
47.03 
1-M High
53.02 
Volume 
589.61K 
Bid
48.05
Ask
48.1
Day Low
46.8 
Open
47.02 
1-M Low
45.57 
Market Cap 
3.76B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 48.45 
20-SMA 48.85 
50-SMA 51.27 
52-W High 58.4 
52-W Low 21.34 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.81/-4.43
Enterprise Value
3.80B
Balance Sheet
Book Value Per Share
12.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ALLRAllarity Therapeutics Inc1.43+0.4887+51.92%0.16PE
After Hours 1.39 -0.04 -2.80%
TNFATNF Pharmaceuticals Inc.0.0779+0.0094+13.72%-- 
After Hours 0.0777 -0.0002 -0.26%
IVVDInvivyd1.03+0.4703+84.03%-- 
After Hours 0.9928 -0.0372 -3.61%
EPIXESSA Pharma0.2631-0.5207-66.43%-- 
After Hours 0.2561 -0.007 -2.66%
MRKRMarker Therapeutics1-0.26-20.63%-- 
After Hours 0.9962 -0.0038 -0.38%
Quotes are at least 15-min delayed:2025/08/26 17:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.